Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s combination therapy uniquely captures the complete antigenic signature of a patient’s own tumor and converts it into a highly stimulatory ‘training program’ for the patient’s immune system. The comprehensive nature of this training is intended to result in both innate and adaptive immune stimulation to optimize long-term anti-tumor effects.
The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer, with additional programs in other types of solid tumors.
Company Details
- Employees
- 25
- Founded
- -
- Address
- 601 Walnut St, Philadelphia,pennsylvania 19106,united States
- Phone
- 215-485-0071
- co****@****vax.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- imvax.com
- Keywords
- Immunotherapy, Biotechnology, Autologous vaccines, Biopharmaceuticals, Glioblastoma Multiforme, Clinical Trials, Research.
- HQ
- Philadelphia, Pennsylvania
Imvax, Inc. Questions
Imvax, Inc.'s helpline number is 215-485-0071
Imvax, Inc.'s website is imvax.com
Imvax, Inc.'s LinkedIn profile is https://www.linkedin.com/company/imvax-inc
Imvax, Inc. has
25 employees.
View email and phone details for 25
employees at Imvax, Inc..
Imvax, Inc.'s industry is
Biotechnology Research
Imvax, Inc.'s top competitors are
Cabaletta Bio,
Aro Biotherapeutics,
Carisma Therapeutics,
Interius Biotherapeutics,
Iovance Biotherapeutics, Inc.,
Spark Therapeutics, Inc.,
Swanbio Therapeutics,
Adaptimmune,
Century Therapeutics, Inc,
Verismo Therapeutics.
Imvax, Inc.'s support email address is contact@imvax.com
Imvax, Inc.'s categories are Biotechnology Research
Imvax, Inc.'s founding year is 2015
